间充质干细胞治疗新型冠状病毒肺炎的研究现状

Research status of mesenchymal stem cell therapy for COVID-19

新型冠状病毒(SARS-CoV-2)引发的新型冠状病毒肺炎(COVID-19)大流行正在全球迅速和持续蔓延,对人类生命健康造成了极大威胁,亟需寻找安全有效的治疗手段。间充质干细胞(MSC)具有强大的免疫调节和抗炎功能,可通过调节免疫细胞的功能、降低炎症因子分泌水平、升高抗炎因子水平以及分泌多种细胞生长因子等方式,来减轻和修复病毒引起的机体过度免疫应答造成的肺损伤及降低发生细胞因子风暴综合征(CSS)和急性呼吸窘迫综合征(ARDS)的风险。此外,间充质干细胞还具有来源丰富、易获取、低免疫原性、无伦理争议、在损伤组织中定向趋化的能力以及有非常强的病毒抵抗力等特性,因此被认为是一种治疗COVID-19的有效方式。本文结合相关研究就MSC治疗COVID-19的安全性、有效性及其可能机制进行评价。

The COVID-19 pandemic caused by SARS-CoV-2 is rapidly and continuously spreading globally, posing a great threat to human life and health.It is urgent to find a safe and effective treatment.Studies have found that mesenchymal stem cells(MSCs)have powerful immunoregulatory and anti-inflammatory functions.They can mitigate and repair lung injury caused by the excessive immune response to the virus and reduce the risk of cytokine storm syndrome(CSS) and acute respiratory distress syndrome(ARDS), by regulating the function of immune cells, reducing the secretion of inflammatory factors, upregulating the anti-inflammatory factors and secreting a variety of cell growth factors.In addition, MSCs are also characterized by abundant sources, easy access, low immunogenicity, no ethical controversy, the ability to target chemotaxis in damaged tissues, and virus resistance.Therefore, it is considered an effective way to treat COVID-19.In this article, we evaluated the safety and efficacy of MSCs in the treatment of COVID-19 and its possible mechanism.